knowledge -WSS

knowledge

author：entertainment 2025-09-30 20:48:10 - browse：4

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Update the Apgar Score to remove skin color

hotspot

WSS

HPV vaccine, cervical cancer study delivers historic results

Medicare bonuses could stop drug shortages under Senate plan

HPV vaccine, cervical cancer study delivers historic results

HPV vaccine, cervical cancer study delivers historic results

Head of FDA's diagnostics center, who led through Covid, retires

TikTok, Instagram influencers need more rules for drug ads

focus

knowledge

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Update the Apgar Score to remove skin color

Hepatitis C has a cure — but many Americans still lack access to it

FDA sets aggressive timeline for overhauling inspection procedures

Apple is now the first public company to be valued at $3 trillion

Immunocompromised patients offer clues on chronic Covid

Activists slam private health insurers over coverage restrictions

High breast density mammograms need follow

The high cost of giving birth even with insurance

Prior authorization reform is both possible and imperative

focus

Immunocompromised patients offer clues on chronic Covid

FDA sets aggressive timeline for overhauling inspection procedures

Pumping milk in bathrooms at health conferences is common

Maisha Meds is a PBM, but don't call it that

High breast density mammograms need follow

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Wikipedia

hotspot

hotspot

knowledge